Startseite // Universität // Aktuelles // Diashow // University hosts co-founder of BioNTech on the future of mRNA vaccines

University hosts co-founder of BioNTech on the future of mRNA vaccines

twitter linkedin facebook email this page
Veröffentlicht am Mittwoch, den 11. Januar 2023

German biotechnology company BioNTech developed the first mRNA-based vaccine approved for use against COVID-19 in 2020, using a molecule called messenger RNA to build immunity.

In a UniTalks online session in English open to the public on Wednesday 18 January 2023 from 12:30 to 13:30, Prof. Özlem Türeci, Chief Medical Officer at BioNTech and Professor for Personalized Immunotherapy at the Helmholtz Institute for Translational Oncology (HI-TRON) and Johannes Gutenberg University Mainz, will detail how the potential of this technology goes far beyond this respiratory infectious disease.

Her talk will shed light on the long-standing research on mRNA-based immunotherapies and emerging directions of mRNA vaccines to prevent and treat other chronic diseases, such as cancer.

Details and link to join the session

Photo: © BioNTech